05 Oct Boston Biomedical Associates Appoints Dr. Sharon Watling as Principal Consultant, Advanced Therapeutics
BBA Bolsters its Roster in the Cell and Gene Therapy Space
MARLBOROUGH, MA— October 5, 2017 – Boston Biomedical Associates (BBA) has appointed Dr. Sharon Watling as Principal Consultant, Advanced Therapeutics to further expand its depth into the gene and cell therapy space. In this role, she will provide clients with clinical and regulatory strategy, clinical study design from oversight to completion and creation of integrated development plans at BBA.
“BBA is a well known CRO that has a highly effective client engagement model and a terrific team,” commented Dr. Watling. “I am excited to join at a time when the company is rapidly expanding and helping clients make advancements in medicine daily.”
Dr. Watling joins BBA with more than 15 years of experience in clinical development, with an emphasis on translational and early stage development, as well as clinical strategies. She brings an extensive background in small molecule and gene and cell therapies to BBA. Before joining the company, she was Senior Director, Esperion Therapeutics and an Independent Clinical/Regulatory consultant for the pharmaceutical industry focusing primarily on clinical development strategy and clinical study design for small molecules, gene and cell therapies. Prior to this she served as Vice President of Clinical Development, Clinical/Regulatory at Aastrom Biosciences, Inc.
“Having an expert in gene and cell therapy like Sharon is going to be a huge asset to our clients as the combination therapy landscape evolved rapidly,” remarked BBA President and CEO Lauren Baker. “With Sharon’s wide-ranging background in industry and education, she brings a depth of understanding of the advanced therapeutics space and will lead this practice at BBA” she added.
Dr. Watling’s industry career started in late stage development within Warner-Lambert/Parke Davis and evolved while at Pfizer to include an early clinical leadership role in Cardiovascular-Metabolic diseases. Following Pfizer, she was Site Leader and Senior Director, Clinical Development at Metabasis, Inc. followed by Research and Development Strategy Leader at Cognigen Corporation.
Dr. Watling also served as Clinical Pharmacist, Research Pharmacy Service at the University of Michigan Hospitals and Health Centers and served on the Oncology Institutional Review Board. Prior to industry, she was an intensive care unit clinical specialist at various academic institutions. Dr. Watling received a Doctor of Pharmacy Degree from the University of Michigan College of Pharmacy.